Protein Sciences

A: We primarily use CHO cells for antibody production. We have made significant investments in optimizing our cell engineering and cell growth processes to achieve high titer expression of antibodies in the CHO cells, enhancing the antibody production efficiency.

A: The antibody production timeline varies depending on several factors, including the type of antibody, the scale of production, and specific client requirements. Using our HTP platforms and high titer expression CHO cells, the timeline could be as fast as 2 weeks, with a daily throughput of 1000+ molecules.

A: Our unique advantage lies in providing valuable insights and guidance to customers throughout the entire antibody drug development process, enabling them to navigate around common pitfalls and overcome challenges effectively. This comprehensive end-to-end viewpoint and approach ensures a seamless and speedy journey from concept to market, making us a trusted and reliable partner for customers in need of antibody production services.

A: For projects involving new molecules, CHO cells are your ideal choice because of our well-established ultra-high-titer CHO expression platform. For projects encountering issues like truncation issues, HEK293 cells are recommended. In cases where your molecules have severe aggregation issues caused by disulfide bonds in CHO or HEK293, NS0 cells can be considered as a last option.

A: An optimal host expresses target antibodies with high titers, optimal glycosylation modifications, low levels of N-linked mannose-5 glycan and afucosylation, and minimal truncations. Additionally, the host should demonstrate efficient transfection, low lactate level, and rapid doubling time.

A: These potential risks include titer variations and different glycosylation and other PTMs, sometimes truncations. The difference may lead to inconsistent efficacy, PK, challenging CMC and late-stage developments. For molecules with therapeutic purposes, it’s highly desirable to use the same CHO host from early discovery to commercial manufacturing.

A: Antibody-dependent cellular cytotoxicity (ADCC) is one of the most important effector mechanisms of tumor-targeting antibodies. The need for ADCC depends on the specific therapeutic strategy and mechanism of action (MOA) of your molecule. You may leverage our CHO-Fut8 technology to enhance ADCC effects.  On the other hand, sometimes ADCC effects must be eliminated, such as T-cell engagers. Antibodies can be engineered to reduce or increase the ADCC effect. Consult our specialists for unique requirements of your project.

A: Afucosylation involves the reduction or removal of fucose in the Fc region of an antibody. This modification can significantly boost the antibody’s affinity for FcγRIIIa on natural killer (NK) cells, which in turn enhances ADCC. Careful MOA studies must be carried out to make the decision. You need to find a balance between efficacy and toxicity.